Citation Impact
Citing Papers
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
2005 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
2005 StandoutNobel
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
2005 StandoutNobel
Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition
2006 StandoutNobel
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
The Hypoxia-Inducible Factor 2α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo
2007 StandoutNobel
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
Stress and Adrenergic Function: HIF1α, a Potential Regulatory Switch
2010
Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies
2008
Update on the management of familial central nervous system tumor syndromes
2007
Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene
2002
Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
2016 StandoutNobel
Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
1999
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis
2009
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
2004 StandoutNobel
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Glioblastoma and Other Malignant Gliomas
2013 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
The dynamic disulphide relay of quiescin sulphydryl oxidase
2012 StandoutNatureNobel
Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII
2011
Ca2+/Calmodulin Kinase-dependent Activation of Hypoxia Inducible Factor 1 Transcriptional Activity in Cells Subjected to Intermittent Hypoxia
2004 StandoutNobel
The biology of VEGF and its receptors
2003 Standout
MicroRNA-92a is a circadian modulator of neuronal excitability in Drosophila
2017 StandoutNobel
HIF-1 Inhibits Mitochondrial Biogenesis and Cellular Respiration in VHL-Deficient Renal Cell Carcinoma by Repression of C-MYC Activity
2007 StandoutNobel
How oxygen makes its presence felt: Figure 1.
2002 StandoutNobel
Hypoxia and adrenergic function: Molecular mechanisms related to Egr-1 and Sp1 activation
2010
von Hippel-Lindau disease
2003 Standout
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
2003 StandoutNobel
Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor
2004 StandoutNobel
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
The semaphorins: versatile regulators of tumour progression and tumour angiogenesis
2008
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation
2003 Standout
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
2006 StandoutNobel
Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
2020
RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma
2008
VHL and Kidney Cancer
2003 StandoutNobel
Induction of human endometrial cancer cell senescence through modulation of HIF‐1α activity by EGLN1
2005
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
2019 StandoutNature
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice
2009
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Angiogenesis as a therapeutic target
2005 StandoutNature
Genome-wide analyses identify transcription factors required for proper morphogenesis of Drosophila sensory neuron dendrites
2006
HIF activation identifies early lesions in VHL kidneys
2002 StandoutNobel
Modulation of carbonic anhydrase activity and its applications in therapy
2004
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
PROLINE HYDROXYLATION AND GENE EXPRESSION
2005 StandoutNobel
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1
2007 StandoutNobel
pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development
2004 StandoutNobel
Tumor‐associated Carbonic Anhydrases and Their Clinical Significance
2006
Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.
2001 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Shingo Ashida being referenced
Novel Lipogenic Enzyme ELOVL7 Is Involved in Prostate Cancer Growth through Saturated Long-Chain Fatty Acid Metabolism
2009
Recent advances in ideas on the molecular pathology and clinical aspects of Von Hippel-Lindau disease
2004
Von Hippel–Lindau Disease: Molecular Pathological Basis, Clinical Criteria, Genetic Testing, Clinical Features of Tumors and Treatment
2006
Germline and Somatic Mutations in von Hippel-Lindau Disease Gene and Its Significance in the Development of Kidney Cancer
1999
Germ‐line Mutation Analysis in Patients with von Hippel‐Lindau Disease in Japan: An Extended Study of 77 Families
2000
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma
2002
Clinical Characteristics of Pancreatic Neuroendocrine Tumors in Japanese Patients With von Hippel-Lindau Disease
2006
Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer
2004
Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma
2006
Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma
2004